U.S. Varicella Cases Drop Sharply Due to Vaccine

This article originally appeared here.
Share this content:
U.S. Varicella Cases Drop Sharply Due to Vaccine
U.S. Varicella Cases Drop Sharply Due to Vaccine

FRIDAY, Aug. 14, 2015 (HealthDay News) -- Varicella cases in the United States have dropped sharply since a vaccine against the disease became available in 1995, according to a study published online Aug. 12 in the Journal of the Pediatric Infectious Diseases Society.

Before 1995, about four million people in the United States got varicella each year, nearly 11,000 were hospitalized, and up to 150 died of the disease, according to the U.S. Centers for Disease Control and Prevention. For this study, CDC researchers analyzed national health insurance claims data. They found that there were 93 percent fewer hospitalizations for varicella in 2012, and 84 percent fewer outpatient visits for the disease than in the period before the vaccine was introduced. After the second dose recommendation took effect in 2006, hospitalizations dropped 38 percent and outpatient visits declined 60 percent.

The largest decrease in varicella occurred among children and teens aged 1 to 19, a group targeted for vaccination against the disease. But there were also significant drops in outpatient visits and hospitalizations among children younger than 12 months -- for whom the vaccine is not recommended -- and among adults, who tend not to get vaccinated.

"We found that, in our study, rates for varicella in the United States continued to decline as the varicella vaccine program has become fully implemented," study coauthor Jessica Leung, M.P.H., said in a journal news release. "We saw significant declines in rates of varicella after the one-dose vaccine was recommended in 1995 in the United States, and we're continuing to see additional declines in varicella after two doses were recommended in 2006."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths